Mankind Pharma (BOM:543904) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Mankind Pharma Debt-to-Equity?

Mankind Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Mankind Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Mankind Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mankind Pharma's Debt-to-Equity or its related term are showing as below:

BOM:543904' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.14
Current: 0.02

During the past 3 years, the highest Debt-to-Equity Ratio of Mankind Pharma was 0.14. The lowest was 0.02. And the median was 0.04.

BOM:543904's Debt-to-Equity is ranked better than
92.61% of 853 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs BOM:543904: 0.02

Mankind Pharma Debt-to-Equity Historical Data

The historical data trend for Mankind Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mankind Pharma Debt-to-Equity Chart

Mankind Pharma Annual Data

Trend

Mar20

Mar21

Mar22

Debt-to-Equity

0.04

0.05

0.14

Mankind Pharma Quarterly Data
	Mar20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					N/A	0.03	N/A	0.02	N/A

Competitive Comparison of Mankind Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mankind Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mankind Pharma's Debt-to-Equity falls into.

Mankind Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mankind Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(8208.91	+	521.84)	/	61552.29
	=	0.14

Mankind Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Mankind Pharma (BOM:543904) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mankind Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mankind Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mankind Pharma (BOM:543904) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mankind Pharma Ltd (BOM:543904) » Definitions » Debt-to-Equity

Traded in Other Exchanges

MANKIND:India

Address

262, Okhla Industrial Estate, Phase-III, New Delhi, IND, 110020

Website

https://www.mankindpharma.com

Mankind Pharma Ltd is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News and Gas-O-Fast.

Mankind Pharma (BOM:543904) Headlines

No Headlines